

Dt. 13th February, 2016

To
The Manager,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Dear Sir,

Sub : Outcome of Board Meeting held on 13th February, 2016

Ref : Scrip Code : 531625

With reference to the cited subject, we submit that, the Board of Directors, at their meeting, held on Saturday, 13th February, 2016 at 11:00 A.M at the registered office of the Company, has inter-alia, considered and approved the following:


1. Un-Audited financial results for the quarter ended on 31st December, 2016, a copy of the same is enclosed herewith, along with the Limited Review Report for the quarter ended 31st December, 2016 is attached herewith.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

For Sangam health Care Product limited


(G S R Murthy)
Compliance Officer

Encl: As above.

LIMITED REVIEW REPORT

To.
The Board of Directors.
Sangam Health Care Products limited


We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, Secunderabad for the quarter and nine months ended 31st December, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2004 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SERI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayant & Sadashiv
Chartered Accountants
FRN No: 001297S


Jayant Palnitkar
Partner
M.No.020851



Date: February 13, 2016
Place: Hyderabad

SANGAM HEALTH CARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31-12-2015

(Rs.in Lakhs)

S.No.	Particulars	Quarter Ended			Year to Date		previous
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
(a)	Net Sales/Income from Operations(Net of Excise duty)	617.56	655.29	607.94	1,898.33	1,952.15	2,517.20
(b)	Other Operating Income	0.00	1.64	0.00	1.72	0.00	475.28
	Total Income	617.56	656.93	607.94	1,900.05	1,952.15	2,992.48
2	Expenditure						
(a)	Cost of material consumed	148.80	210.48	219.79	586.83	754.69	1,228.60
(b)	Purchase of stock - in - trade	0.00	0.00	0.00	0.00	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	36.86	(63.66)	(36.73)	(40.40)	(36.67)	0.00
(d)	employee benefits expenses	81.39	108.60	118.58	303.84	322.08	406.11
(e)	Depreciation and Amortization Expenses	37.81	37.81	43.06	113.43	129.19	151.24
(f)	Other Expenditure (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	194.34	158.77	242.19	572.73	758.70	928.05
	Total Expenses	499.20	452.00	586.89	1,536.43	1,927.99	2,268.12
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	118.36	204.93	21.05	363.62	24.16	724.36
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	118.36	204.93	21.05	363.62	24.16	724.36
6	Finance Cost	108.41	131.93	129.54	336.28	387.57	545.82
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)	9.95	73.00	(108.49)	27.34	(363.41)	178.54
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax (7+8)	9.95	73.00	(108.49)	27.34	(363.41)	178.54
10	Tax expenses	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	9.95	73.00	(108.49)	27.34	(363.41)	178.54
12	Extraordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit/Loss for the period (11+12)	9.95	73.00	(108.49)	27.34	(363.41)	178.54
14	Share of Profit/(loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest*	0	0	0	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)*	9.95	73.00	-108.49	27.34	-363.41	178.54
17	Paid-up Equity share capital (Face value of the Rs 10 each)	1486.07	1486.07	1486.07	1486.07	1486.07	1486.07
18	Reserve excluding Revaluation reserves as per balance Sheet of previous account year	nil	nil	nil	nil	nil	nil
19.i	Earnings Per Share (EPS) in Rupees (before & after extraordinary itmes) (not annualised)	0.01	0.05	-0.07	0.02	-0.24	0.12
	see accompanying note to the financial results						

Note :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 13.02.16
- The Segment reporting as defined in Accounting Standard-17 is not applicable, as the operation of the Company are related to one Segment
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.
- Pursuant to the enactment of the Companies Act 2013 (The Act the Company has effective,, 1st April, 2014 reviewed & revised the estimated useful lives of its fixed assets, generally in accordance with the provision of the Schedule II to the Act. The consequential impact (after considering the transaction provision specified in Schedule II) on the depreciation charges & on the result for the quarter is not material.
- The Statutory Auditors have carried out a limited review report of the financial results for the quarter ended 31.12.2015, in accordance with Regulation 33 of SEBI(LODR)Regulations. 2015.

Place : Secunderabad
Date : 13.02.2016

For SANGAM HEALTH CARE PRODUCTS LIMITED
Abhishek
MANAGING DIRECTOR

